GlassScriptPhysician profile
Kyle L Wagamon
NPI 1780758003
$1,522.29
in general payments reported to CMS, 2019-2025
19 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $27.00 · 2021: $559 · 2022: $46.55 · 2023: $44.43 · 2024: $207 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $545.00 | 2021 | |
| Abbvie INC. | $480.29 | 2019-2025 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $76.52 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $59.83 | 2019 | |
| Arcutis Biotherapeutics, INC. | $59.59 | 2023-2024 | Zoryve |
| Leo Pharma INC. | $45.35 | 2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $44.44 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $29.96 | 2024 | |
| Lilly USA, LLC | $28.89 | 2019 | |
| Pfizer INC. | $24.55 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.11 | 2024 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $18.78 | 2019 | |
| Dermira, INC. | $18.35 | 2019 | |
| Amgen INC. | $15.19 | 2019 | |
| Merck Sharp & Dohme LLC | $15.01 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $14.43 | 2025 | Sofdra |
| Mission Pharmacal Company | $14.34 | 2020 | |
| Vyne Pharmaceuticals INC. | $12.66 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Wagamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.